26. Antihypertensive Agents Flashcards

1
Q

what is map

what is co

how do bp meds produce effects

A

MAP = CO × SVR

CO = SV × HR
(SV depends on preload, contractility and afterload)

Antihypertensive agents will produce their effect by modulating cardiac output (CO),
systemic vascular resistance (SVR) or both.

The easiest way to
categorise antihypertensive agents
is according to their site of action:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Heart:

A

1
> β-Blockers –
Competitive antagonists at β-adrenoceptors
with varying degrees of receptor selectivity.

Negative inotropic and chronotropic
effects reduce CO

while antagonism of the renal
β1 adrenoceptors reduces sympathetically
mediated release of renin.

• Atenolol, esmolol and metoprolol –
Cardioselective
(i.e. act only on β1 adrenoceptors at normal doses).

• Propranolol – Non-cardioselective

(i. e. acts at both β1 and β2
adrenoceptors) .

• Labetalol – Non-cardioselective and 
has antagonistic action at
α1-adrenoceptors 
(ratio of α1: β blockade 
depends on the route of
administration: oral = 1:3 and IV = 1:7).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Blood vessels:

A

> Directly acting vasodilators –

Produce NO, which acts on 
G-protein coupled receptors 
activating guanylate cyclase 
and increasing intracellular
 cGMP levels to cause vasodilatation.

• Sodium nitroprusside and hydralazine –

Produce vasodilatation of 
both arterial and venous vessels. 
Arterial vasodilatation reduces SVR 
while venous vasodilatation 
increases venous capacitance and
reduces preload.

• Glyceryl trinitrate and isosorbide mononitrate –

Produce vasodilatation of primarily
the venous vessels.

This increases venous capacitance
and reduces preload.

> Indirectly acting vasodilators –

Reduce SVR and preload by various
mechanisms.

• Calcium channel blockers 
(e.g. amlodipine) – 
Antagonists at L-type
calcium channel located in 
vascular smooth muscle.

• α-Blockers (e.g. prazosin) –
Antagonists at α1-adrenoceptors
causing vasodilatation of
both arterial and venous vessels.

• Potassium channel activators 
(e.g. nicorandil) – 
Activators of AT P-sensitive 
K+ channels within arterioles 
causing hyperpolarisation,
reduced intracellular Ca2+ 
levels and hence arteriolar vasodilatation.

Venous vessels are also relaxed by
activation of guanylate cyclase by
the nitrate moiety within nicorandil.

• Magnesium – This is a natural antagonist to calcium.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Kidney

A

Kidney:

> Diuretics –

Reduce plasma volume
(which reduces preload and CO)

and some produce 
arteriolar vasodilatation 
reducing SVR (
e.g. thiazide and
loop diuretics). See Chapter 27, ‘Diuretics’.

> Agents affecting the renin–angiotensin–aldosterone system
(See later)
• Angiotensin-converting enzyme inhibitors,
ACEI (e.g. ramipril)

• Angiotensin II receptor antagonists (e.g. losartan)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Central nervous system:

A

> Centrally acting drugs
(e.g. clonidine and methyldopa) –
Stimulate central inhibitory presynaptic
α2-adrenoceptors causing reduced
noradrenaline release
and hence
reduced centrally mediated sympathetic outflow.

> Ganglion blockers (e.g. trimetaphan) –
Competitive antagonists at
nACh receptors located in
parasympathetic and sympathetic ganglia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Briefly explain the renin–angiotensin–aldosterone

system (RAAS).

A

RAAS system is intricately
involved in the regulation of blood pressure.

Renin is released from the
juxtaglomerular apparatus

in response to
low renal perfusion,
reduced Na+ at the macula densa
or sympathetic stimulation

via renal β1 adrenoceptors.

Renin converts angiotensinogen,
which is produced by the liver,

into angiotensin I.

Angiotensin I is then
converted into angiotensin II
in the lung via the action of
angiotensin-converting enzyme (ACE).

Angiotensin II produces a multitude of 
effects including 
peripheral vasoconstriction, 
aldosterone release from the adrenal cortex, 
increased thirst sensation, 
and increased ADH 
(also known as vasopressin) 
and ACTH release from the 
hypothalamo–pituitary axis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are some of the more
common side effects of
antihypertensive agents

A
> β-Blockers – 
Unwanted side effects come from 
antagonism of β2 adrenoceptors, 
which may cause 
bronchospasm and peripheral vasoconstriction.
Hence these agents are best 
avoided in patients with 
COPD and peripheral vascular disease.

> Vasodilators –

Vasodilatation of the
capacitance vessels can cause
postural hypotension while

vasodilatation of
cerebral vessels
can lead to headaches.

> Diuretics – 
Loop and thiazide diuretics 
can both lead to 
hyponatraemia,
hypokalaemia, 
hypomagnesaemia 
and hypochloraemic alkalosis due

to their action on renal electrolyte reabsorption.

Loop diuretics can also cause ototoxity
leading to deafness

while thiazide diuretics can
cause hyperuricaemia
and precipitate gout.

Owing to the risk of hypokalaemia,
these agents should be used cautiously with digoxin.

> ACEI –

Under normal conditions 
angiotensin II maintains renal perfusion
by altering the calibre 
of the efferent arteriole 
at the glomerulus. 

However, in the presence of an
ACEI this mechanism is lost
and renal perfusion
pressure may fall,

leading to renal failure in those individuals
who already have impaired renal circulation.

Hence these agents are contraindicated
in renal artery stenosis.

Some patients may experience a persistent
cough due to
increased bradykinin,
which is normally degraded by ACE.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NIMODIPINE

A
NIMODIPINE
Dihydropyridine calcium
channel antagonist
• Tablets: 30 mg
• Solution: 200 μg/mL

DOSE
• Oral: 60 mg 6x/day for SAH
• IV: 1–2mg/hr

MOA
• Competitive antagonist
at slow calcium
channels causing
decreased influx of Ca2+
into cells
• Relatively selective for
cerebral arterioles

METABOLISM
AND EXCRETION
• Hepatic metabolism
• Excreted in urine

ABSORPTION/
DISTRIBUTION
• Well absorbed orally
• Significant fist-pass
metabolism
  • Oral bioavailability up to 28%
  • Protein binding 98%
  • VD 0.94–2.3 L/kg

USES
• Reduction of vasospasm following subarachnoid
haemorrhage (SAH)

• Migraine

EFFECTS

CVS
• ↓ SVR and BP at > 2 mg/hr
CNS

• Increased cerebral blood
flow secondary to
vasodilatation

  • Headache
  • Vertigo
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

NIFEDIPINE

prep

dose

uses

MOA

ADME

A
NIFEDIPINE
Calcium channel antagonist
• Capsules: 5–10 mg
• Tablets: 10–60 mg
• Onset in: 15–20 min

DOSE
• 10–20 mg 8 hourly

USES
• Angina
• Hypertension
• Reduction of vasospasm during coronary angiography
• Raynaud’s phenomenon
MOA
• Competitive antagonist
at slow calcium
channels causing
decreased influx of
Ca2+ into cells

ABSORPTION/
DISTRIBUTION

  • Well absorbed orally
  • Oral bioavailability 60%
  • Protein binding 95%
  • t½ 5 hours

METABOLISM
AND EXCRETION
• Hepatic metabolism
• Excreted in urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

EFFECTS

Nifedipine

A
EFFECTS
CVS
• ↓ SVR and BP
• ↑ HR and ↓ contractility
• ↑ CO
• ↑ Coronary oxygen
requirements
• Sublingual administration
can cause precipitous fall in
BP

• Flushing

CNS
• Small increased cerebral
blood flow secondary to
vasodilatation

  • Headache
  • Vertigo

RS
• Inhibits hypoxic pulmonary
vasoconstriction

OTHER
• Negatively inotropic effects
of nifedipine are additive
with those of the volatiles,
especially isoflurane. Use
together with caution
• ↓ MAC
• Prolong effects of
neuromuscular blocking
drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CAPTOPRIL

A

CAPTOPRIL
ACE Inhibitor

• Tablets: 12.5/25/50 mg

DOSE

• Oral: 12–50 mg/day,
starting
at 6.25 mg and titrating up

MOA
• Angiotensin converting enzyme
(ACEI)

preventing conversion of
angiotensin I to II

USES
• Hypertension

  • Reduction of progression of diabetic nephropathy
  • Post MI, to improve ventricular remodelling

ABSORPTION/
DISTRIBUTION

  • Well absorbed orally
  • Oral bioavailability 75%
  • Protein binding 30%
  • VD 0.61–0.79 L/kg
  • t½ 1.9 hours

METABOLISM
AND EXCRETION

  • Hepatic metabolism
  • Excreted in urine, 50% unchanged
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Captopril effects

A

EFFECTS
CVS
• ↓ SVR and BP

  • Afterload ↓ > preload
  • First-dose hypotension – give test dose at night

RENAL
• Angiotensin II (AII) autoregulates renal
perfusion pressure by altering arteriolar tone.

ACEI reduce plasma AII,
which can cause ↓ perfusion
and = renal failure

• So, contraindicated in renal
artery stenosis

METABOLISM
• ↓ Aldosterone leads to
↑ renin secretion

• ↑ K+ 
(as less exchanged for
Na+) 
so avoid using with K+
sparing diuretics

OTHER

• Can cause refractory
hypotension with
anaesthesia – 
some advise
omitting for 24 hours prior to
surgery

• Dry cough results from ↑
serum bradykinin

• Angio-oedema (more
common in Afro-Caribbean
patients)

  • Agranulocytosis
  • Thrombocytopenia
  • Rash, ulcers

• Caution with NSAIDs –
increase chance of renal
failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

LOSARTAN

A

LOSARTAN
Substituted imidazole AII receptor antagonist

• Tablets: 25/50 mg

DOSE
• 50–100 mg/day

MOA
• Antagonist at angiotensin II
receptors

USES
• Hypertension

• To reduce progression of
diabetic nephropathy,

independent of its
antihypertensive effect

• Used when dry cough of
ACE inhibitors unacceptable

• Not usually first line,
as more expensive than ACE inhibitor

METABOLISM
AND EXCRETION

  • Hepatic metabolism
  • Excreted in urineand bile

ABSORPTION/
DISTRIBUTION
• Well absorbed orally
• Significant first-pass metabolism

  • Oral bioavailability 30%
  • Protein binding 99%
  • VD 0.61–0.79 L/kg
  • t½ 2 hours
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

LOSARTAN

effects

A

EFFECTS
CVS
• ↓SVR and BP

• Afterload ↓ > preload

• first-dose hypotension –
give test dose at night

RENAL
• Angiotensin II (AII)
autoregulates renal
perfusion pressure by
altering arteriolar tone and
so antagonists can cause
↓ perfusion and renal
failure

• So, contraindicated in
renal artery stenosis

OTHER
• Can cause refractory
hypotension with
anaesthesia – some advise
omitting for 24 hours prior
to surgery

• Does not block actions of
ACE, therefore no increase
in bradykinins and no
cough

• Caution with NSAIDs –
increased chance of renal
failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

NICORANDIL

A

Nicotinamidoethyl nitrate

K+ channel activator

• Tablets: 10/20 mg

DOSE
• 10–30 mg 12 hourly

MOA

• Activates K+ channels,
 i.e.
opens them. K+ flows out
of cell hyperpolarising the
membrane
• This closes Ca2+
channels, 
reducing Ca2+
concentration and
decreasing contractility
and cardiac work
• Causes venous relaxation
and reduction of preload
by donating nitric oxide to
cells. 
This increases cGMP 
and reduces Ca2+

(see GTN, next page, for
full explanation)

METABOLISM
AND EXCRETION
• Hepatic metabolism
• Excreted in urine
and bile
ABSORPTION/
DISTRIBUTION
• Well absorbed orally
• Protein binding 0%
• t½ 1 hour

USES
• Angina – treatment
and prophylaxis

EFFECTS
CVS
• ↓Preload
• ↓ LVEDP
• ↓ Cardiac work
• Flushing

CNS
• Vertigo
• Headache

OTHER
• Nausea and vomiting
• Angio-oedema
• Hepatic dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

GLYCERYL TRINITRATE (GTN)

A

GLYCERYL TRINITRATE (GTN)

Organic Nitrate

  • Tablets: 300/600 μg S/L
  • Buccal: 2/5 mg prn
  • Spray: 400 μg/spray S/L prn
  • Patch: 5–10 mg/24 hours

• Solution: 5 mg/mL infused
at 1–10 mg/hr titrated to BP

• Sublingually – effective in
3 min lasts 1 hour

MOA
• GTN broken down to
liberate nitric oxide (NO)

• NO increases cGMP,
so Ca2+ uptake into smooth
muscle is reduced
leading to vasodilation

CHEMICAL PROPERTIES
• Explosive, so remove
patches before
cardioversion

METABOLISM
AND EXCRETION
• Hepatic metabolism
to di/mononitrites

• Excreted in urine

ABSORPTION/
DISTRIBUTION
• Well absorbed orally
• Significant first-pass
metabolism
• Oral bioavailability 5%
• Protein binding 60%
• VD 0.04–2.9 L/kg

USES
• Prophylaxis/treatment of
angina

• CCF and pulmonary
oedema

  • MI, ACS
  • Hypertension

• Patch over vein to
maintain dilation, e.g. for
peripheral feeding

EFFECTS
CVS
• ↓ SVR and BP

• Predominantly
venodilatation so ↓
preload
CNS
• ↑ ICP causing headache
OTHER
• Tolerance develops to
patches, so have
‘patch-free period’ each
day

• No significant tolerance
develops to IV infusion

• Methaemoglobinaemia
(rare)

17
Q

CLONIDINE

A

Tablets: 100/250/300 μg

• Solution: 150 μg/mL

DOSE

  • Oral: 50–600 μg 8 hourly
  • IV: 75–300 μg 8 hourly

MOA

• Agonist at presynaptic a2
receptors,
so decreasing
sympathetic tone

• In spinal cord they
increase release of
endogenous opiates

• Effective within 10 min

METABOLISM
AND EXCRETION

  • Hepatic metabolism
  • Excreted in urine, 50% unchanged

ABSORPTION/
DISTRIBUTION

  • Well absorbed orally
  • Oral bioavailability 100%
  • Protein binding 20%
  • VD 2l L/kg
  • t½ 9–18 hours

USES

• Hypertension

• Agitation and anxiety
on ICU

• Adjunct in neuroaxial
anaesthesia

  • Migraine
  • Analgesia

EFFECTS
CVS
• ↓ SVR and BP

• Rebound hypertension if
stopped suddenly

CNS
• Sedation, anxiolysis
• ↓ MAC

RENAL

• Diuresis?
result of ADH
inhibition

HAEMATOLOGICAL
• No increase in platelet
aggregation, 
despite
their surface a2
receptors

OTHER

• ↓ Post-operative
analgesia requirements

18
Q

SODIUM NITROPRUSSIDE

A

SODIUM NITROPRUSSIDE

• Red/brown powder
50 mg/vial

• Reconstitute with 5%
dextrose

DOSE
• 0.5–6 μg/kg/min titrate
to effect

CHEMICAL PROPERTIES
• Biodegrades in sunlight
so use opaque giving
sets or wrap normal
ones in tin foil

MOA
• Broken down to
liberate nitric oxide (NO)

• NO increases cGMP,
so Ca2+ uptake into smooth
muscle is reduced leading
to vasodilation

USES
• Hypertension

19
Q

SNP

ADME

EFFECTS

A

METABOLISM
AND EXCRETION
• Metabolised two ways:

1 Reacts with sulfhydryl
groups on plasma proteins

2 Hydrolysis in red blood
cells to liberate NO +
5 cyanide (CN– ) ions +
methaemoglobin.

• Of the 5 CN-s:

• 1 CN– reacts with Hb
-> cyanomethaemoglobin

• 4 CN– enter plasma,
and of these:

• 3 CN– react with
thiosulphate ->
thiocyanate

• 1 CN– reacts with
hydroxy-cobalamin ->
cyanocobalamin

ABSORPTION/
DISTRIBUTION
• Not absorbed orally
• t½ 10 min

EFFECTS

CVS
• Arteriolar dilation,
↓ SVR and BP

  • Venodilatation, ↓preload
  • ↓ LVEDP
  • ↓ Myocardial O2 consumption

RS
• ↓ Hypoxic pulmonary
vasoconstriction,
so give O2 to reduce shunt

CNS
• ↑ ICP
• Dizziness

ENDOCRINE
• ↑ Catecholamines
• ↑Renin

TOXICITY
• Cyanide irreversibly inhibits
respiration by binding to
cytochrome oxidase

  • Signs:
  • Tachycardia, arrhythmias
  • Hyperventilation
  • Sweating
  • Rising SVO2
  • Metabolic acidosis
  • More common in
  • Liver/renal failure
  • Vit B12 deficiency

OTHER
• Nausea and vomiting
• Muscle twitching
• Tachyphylaxis

20
Q

METHYLDOPA

A

Phenylalanine derivative

  • Tablets: 125/250/500 mg
  • Solution: 50 mg/mL

DOSE
• 0.5–3 g/day
in 2–3 doses

MOA

• Metabolised to a -methyl
noradrenaline,
which is an
a2 agonist

• This is taken up into
nerve terminals in CNS,
and when released decreases sympathetic tone

METABOLISM
AND EXCRETION
• Hepatic metabolism
• Excreted in urine,
50% unchanged
ABSORPTION/
DISTRIBUTION
• Variable oral absorption
• Undergoes first-pass
metabolism
• Variable oral
bioavailability 8–60%
• Protein binding < 20%
USES
• Hypertension
• Pregnancy induced
hypertension and
pre-eclampsia
21
Q

METHYLDOPA

A

EFFECTS
CVS
• ↓ SVR and BP

• Postural hypotension
(rare)

• Rebound hypertension if
stopped suddenly

CNS
• Sedation
• Vertigo
• Depression, nightmares
(uncommon)
RENAL
• Urine darkens on
standing due to oxidation
of methyldopa and its
metabolites
GI
• Constipation
• Impaired liver function
with long-term use
• Hepatic necrosis reported
HAEMATOLOGICAL
• Direct Coombe’s test + in
10–20%
• Haemolytic anaemia
• Thrombocytopenia (rare)
• Leucopenia (rare)
OTHER
• Decreases MAC
• Hypersensitivity to drug
can cause myocarditis
• Gynaecomastia
22
Q

PRAZOSIN

A

PRAZOSIN

Quinazoline derivative

• Tablets:
0.5/1/2/5 mg

DOSE
• 0.5 mg t.d.s.
increasing to
max of 20 mg/day

MOA
• Highly selective a1
competitive antagonist

ABSORPTION/
DISTRIBUTION
• Oral bioavailability
50–80%
• Protein binding 92%
• VD 0.5–0.89 L/kg

METABOLISM
AND EXCRETION
• Hepatic metabolism
• Excreted in bile

USES
• Hypertension
• Benign prostatic
hypertrophy
• Raynaud’s phenomenon
• Treatment of nightmares
associated with posttraumatic
stress disorder
EFFECTS
CVS
• a1 blockade
• Vasodilation and ↓ BP
• Little reflex tachycardia

GU
• Relaxes bladder
sphincters

SIDE-EFFECTS
• Profound orthostatic
hypotension
• Syncope
• Nasal congestion
• Fatigue
• Headache
• Vertigo
• Nausea and vomiting
These side-effects may be
pronounced after the first
dose (‘first-dose effect’),
but may resolve with
continued use
23
Q

PHENOXYBENZAMINE

A

PHENOXYBENZAMINE
a-blocker

  • Capsules: 10 mg
  • Solution: 50 mg/mL

DOSE
• Oral: 10–60 mg per day
in divided doses

• IV: 10–40 mg over
1 hour Lasts for 3–4 days

MOA
• Non-selective irreversible
a-blocker

• New receptors must be
synthesised to overcome
drug effect

• Blockade of a2 receptors
increases the amount of
noradrenaline released

• Partial agonist at 5-HT2
receptors

ABSORPTION/
DISTRIBUTION
• Oral bioavailability
25%

  • Protein binding 50%
  • t½ 24 hours

USES
• Hypertensive emergencies,
especially caused by

  • Phaeochromocytoma
  • Cocaine

• Reynaud’s phenomenon

• Complex regional pain syndrome,
because it modulates the
sympathetic nervous system

24
Q

PHENOXYBENZAMINE

ME

EFFECTS

A
METABOLISM
AND EXCRETION
• Hepatic metabolism
• Excreted in urine
and bile

EFFECTS

CVS
• a1 blockade

• Vasodilation and ↓BP

• Reflex tachycardia
causes ↑ CO

• a2 blockade enhances
noradrenaline release
causing ↑ HR and ↑ CO

CNS
• Sedation
• Meiosis
• Convulsions with rapid
infusion
• Dizziness
OTHER
• Little effect on GI/renal
blood flow
• Dry mouth
• Impotence
• Contact dermatitis
25
Q

PHENTOLAMINE

A

PHENTOLAMINE

Imidazoline

• Pale yellow solution:
10 mg/mL

DOSE
• 1–5 mg titrate to effect

  • Onset in 1–2 min
  • Offset in 5–20 min

MOA
• Competitive a blocker

• 3x higher affinity for a1
than a2

  • b receptor agonist activity
  • Anti-serotonergic activity

USES
• Hypertensive emergencies, especially caused by:

  • Phaeochromocytoma
  • Cocaine
  • MAOI reactions with tyramine
  • Inject into corpus callosum to facilitate erection in impotence

• Used in diagnosis and treatment of
complex regional pain syndrome as this
has an element of sympathetic mediation

26
Q

PHENTOLAMINE

A

METABOLISM
AND EXCRETION

• Extensively
metabolised

• 10% excreted
unchanged in urine

ABSORPTION/
DISTRIBUTION
• Oral bioavailability 20%
• Protein binding 50%
• t½ 15 min
EFFECTS
CVS
• a1 blockade
 • Vasodilation and ↓ BP
 • ↑ Coronary artery
      perfusion

• ↓ Pulmonary artery
pressure

• a2 blockade
• Enhances noradrenaline
release causing ↑ HR and
↑ CO

• Marked nasal congestion,
use topical vasoconstrictors
if planning nasal instrumentation

RS
• ↑ VC and ↑ FEV1

• ↑ Secretions

• Prevents bronchospasm
caused by histamine release

GI
• GI motility
• Salivation
• Gastric acid secretions

OTHER
• Insulin secretion

27
Q

B BLOCKERS

Class II antiarrhythmic

A

B BLOCKERS
(Class II antiarrhythmic)

MOA
• All competitive
antagonists at b adrenoreceptor

• Some have intrinsic
sympathomimetic activity

• Varying receptor affinity
(see box below)

RECEPTOR SELECTIVITY
Aim to block b1 but not
b2 receptors

‘Cardioselective’ drugs:
• Atenolol
• Esmolol (ultra-short acting)
• Metoprolol (short acting)
• Bisoprolol
• Carvedilol
NB all will act on b2 if dose
high enough
USES
• Hypertension
• Angina and MI
• Tachycardias
• Obtund reflex
hypertension during
laryngoscopy, e.g.
esmolol
• In phaeochromocytoma
– pre-op stabilisation
• HOCM
• Anxiety
• Glaucoma
• Migraine prophylaxis